Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer - Slamon, D J; Fasching, P A; Hurvitz, S (Ther Adv Med Oncol, 2023)
17588359231178125